Skip to content

Auriculotherapy in the treatment of gestational nausea and vomiting: a randomized clinical trial

Technological innovations and integrative and complementary therapies in obstetric care

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-4wtq84v
Enrollment
Unknown
Registered
2022-01-13
Start date
2022-05-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea and Vomiting

Interventions

Treated group: 25 pregnant women will receive semi-permanent needles and 25 pregnant women will receive low-level laser, both groups at specific auricular points for the treatment of nausea and vomiti
D020831

Sponsors

Universidade Estadual de Londrina
Lead Sponsor
Universidade Estadual de Londrina
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Pregnant women referred to the AEHU (Ambulatório de Especialidades do Hospital Universitário) from prenatal care at usual risk will be included, and pregnant women at usual risk attended at the basic health units of the network of the city of Londrina, Paraná, with chronological age over 18 years old; gestational age between 5 and 16 weeks confirmed by ultrasound, regardless of parity, who report symptoms of nausea and/or vomiting of a mild degree (PUQE score less than 6) or moderate (PUQE score between 7 and 11) *PUQE: (Pregnancy Unique Quantification of Emesis)

Exclusion criteria

Exclusion criteria: Pregnant women with diagnosed mental retardation and suicidal idealization will be excluded; coagulation disorders; in pharmacological treatment for psychosomatic illness such as anxiety and depression; hyperthyroidism; dermatological lesion in the pinna; unexplained fever; multiple pregnancy; gestational trophoblastic disease, hyperemesis gravidarum; use of antiemetic; diarrhea; pregnant women with fetuses with Down syndrome, and pregnant women afraid to receive the semi-permanent needle

Design outcomes

Primary

MeasureTime frame
The primary outcome is the reduction in nausea and vomiting during pregnancy, assessed using the Pregnancy Score Unique Quantification of Emesis (PUQE) instrument, a Likert scale with 5 options, answering 3 basic questions related to gestational nausea and vomiting. It will also be evaluated by reactivity to palpation at the points, classified as Grade I (the participant verbally reports the pain), II (the participant expresses pain through the face), and III (the participant tries to prevent the examination by removing the head or bringing your hand to the examiner's hand).

Secondary

MeasureTime frame
The secondary outcome is the quality of life of pregnant women with gestational nausea and vomiting, verified through the instrument Health-Related Quality of Life Questionnaire for Nausea and Vomiting of Pregnancy (NVPQOL) – translated and validated version in Portuguese.

Countries

Brazil

Contacts

Public ContactThelma Sodre

Universidade Estadual de Londrina

thelmalagutti@gmail.com5543998092222

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 2, 2026